News articles about Athersys (NASDAQ:ATHX) have trended somewhat positive recently, according to Accern Sentiment Analysis. Accern rates the sentiment of press coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Athersys earned a daily sentiment score of 0.12 on Accern’s scale. Accern also assigned news stories about the biopharmaceutical company an impact score of 45.8774676587959 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.
Here are some of the headlines that may have impacted Accern’s analysis:
- Insider Selling: Athersys, Inc. (ATHX) Insider Sells 14,000 Shares of Stock (americanbankingnews.com)
- Athersys to Present at Needham Healthcare Conference on March 28 (feeds.benzinga.com)
- Technical Secrets – Athersys Inc (NASDAQ: ATHX) – Stocks Market Cap (stocksmarketcap.com)
- Athersys, Inc. (ATHX) EVP John J. Harrington Sells 15,000 Shares (americanbankingnews.com)
- Athersys’ (ATHX) Buy Rating Reiterated at Maxim Group (americanbankingnews.com)
Several brokerages recently weighed in on ATHX. ValuEngine raised Athersys from a “sell” rating to a “hold” rating in a research note on Thursday. Maxim Group reaffirmed a “buy” rating and set a $6.00 target price on shares of Athersys in a research note on Tuesday, March 13th.
Athersys (NASDAQ:ATHX) last announced its quarterly earnings data on Tuesday, March 13th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.07) by ($0.04). Athersys had a negative return on equity of 123.22% and a negative net margin of 869.50%. The business had revenue of $1.17 million during the quarter, compared to analysts’ expectations of $0.42 million. During the same period in the prior year, the company posted ($0.10) earnings per share. The firm’s revenue was up 19.0% on a year-over-year basis. equities research analysts expect that Athersys will post -0.34 earnings per share for the current year.
In other news, insider William Lehmann, Jr. sold 14,000 shares of the firm’s stock in a transaction dated Tuesday, March 20th. The stock was sold at an average price of $1.89, for a total transaction of $26,460.00. Following the completion of the sale, the insider now directly owns 481,973 shares of the company’s stock, valued at approximately $910,928.97. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, EVP John J. Harrington sold 15,000 shares of the firm’s stock in a transaction that occurred on Friday, March 16th. The shares were sold at an average price of $1.84, for a total value of $27,600.00. The disclosure for this sale can be found here. 9.40% of the stock is owned by company insiders.
COPYRIGHT VIOLATION NOTICE: “Athersys (ATHX) Receives Media Sentiment Score of 0.12” was first published by BBNS and is owned by of BBNS. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://baseballnewssource.com/2018/03/22/athersys-athx-receives-daily-news-impact-score-of-0-12/1925596.html.
Athersys, Inc is an international biotechnology company that is focused primarily in the field of regenerative medicine. The Company’s MultiStem cell therapy, an allogeneic stem cell product, is its lead platform product and is in later-stage clinical development. Its clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the standard of care is limited or inadequate for many patients.
Receive News & Ratings for Athersys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Athersys and related companies with MarketBeat.com's FREE daily email newsletter.